Besides Keytruda, there are only 2 other approved oncology drugs in Merck's portfolio.

Source: https://seekingalpha.com/article/4608259-merck-solid-pharma-buy-strong-upside-if-keytruda-patents-extended?source=feed_all_articles

It's also been the best-performing large-cap pharma name in 2022, on the back of strong progress with its mega blockbuster drug Keytruda.

Source: https://seekingalpha.com/article/4567396-schwab-schd-etf-great-dividend-growth-pick?source=feed_all_articles

Keytruda — provider of 35% of Merck’s revenue over the last three years — and Bristol’s Opdivo will both become potential candidates for negotiations in 2028.

Source: https://time.com/6308892/drug-price-negotiations/

Keytruda revenue is expected to top $24 billion this year and could exceed $30 billion as soon as 2026, according to analyst estimates.

Source: https://gazette.com/news/us-world/drugmakers-go-under-the-skin-skirting-early-us-medicare-price-negotiations/article_e1e20b6a-11cb-5f89-af68-09345c21fe73.html

Moderna Chief Executive Officer Stephane Bancel told CNBC recently that the company is moving aggressively into Phase 3 studies with the belief that “anywhere Keytruda works, this should work.”

Source: https://rapidcityjournal.com/opinion/columnists/lisa-jarvis-cancer-vaccine-hunt-makes-progress-finally/article_dbc577e9-41c2-5490-9349-a77c6a27e369.html

Oncology sales growth was largely due to a 20% increase in sales of Keytruda.

Source: https://seekingalpha.com/article/4609658-merck-keytrudas-continued-oncology-success-and-other-prospects?source=feed_all_articles